Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Inge A.T. Hermens
Observed name:
Inge Hermens
Observed institutions:
Radboud University Nijmegen,
Radboud University Medical Center,
Radboud Institute for Molecular Life Sciences,
Byondis BV (Netherlands)
ORCID:
0000-0002-2890-3231
Observed ORCID:
0000-0002-2890-3231
OpenAlex ID:
A5000924696
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses
2021
·
Jesper van Eck van der Sluijs
, Diede van Ens
, et al.
·
Cancer Immunology Immunotherapy
·
27
PDF
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
·
Molecular Cancer Therapeutics
·
13
PDF
Abstract 926: BYON3521, a novel effective and safe c-Met targeting antibody-drug conjugate
2021
·
Patrick Groothuis
, Danielle Jacobs
, et al.
·
Cancer Research
·
4
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2025
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
Supplementary Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
Supplementary Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023
·
Patrick G. Groothuis
, Daniëlle C.H. Jacobs
, et al.
Show more works
View as search
Works count:
11
Citation count:
44
H-index:
3
I10-index:
2
Year
Topic
Type
